Vontobel Holding Ltd. Sells 63 Shares of Chemed Co. (NYSE:CHE)

Vontobel Holding Ltd. cut its holdings in shares of Chemed Co. (NYSE:CHEFree Report) by 7.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 765 shares of the company’s stock after selling 63 shares during the period. Vontobel Holding Ltd.’s holdings in Chemed were worth $447,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CHE. Kayne Anderson Rudnick Investment Management LLC lifted its stake in shares of Chemed by 3.4% in the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 534,123 shares of the company’s stock valued at $277,584,000 after acquiring an additional 17,487 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Chemed by 0.3% in the 3rd quarter. Wellington Management Group LLP now owns 386,237 shares of the company’s stock valued at $200,727,000 after acquiring an additional 1,044 shares during the last quarter. Impax Asset Management Group plc lifted its stake in shares of Chemed by 4.2% in the 3rd quarter. Impax Asset Management Group plc now owns 311,191 shares of the company’s stock valued at $161,726,000 after acquiring an additional 12,608 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Chemed by 9.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 287,386 shares of the company’s stock valued at $149,355,000 after acquiring an additional 24,161 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. lifted its stake in shares of Chemed by 2.2% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 228,040 shares of the company’s stock valued at $118,513,000 after acquiring an additional 4,802 shares during the last quarter. 95.85% of the stock is currently owned by institutional investors.

Chemed Stock Up 2.0 %

NYSE CHE opened at $616.51 on Wednesday. The company has a market capitalization of $9.32 billion, a price-to-earnings ratio of 34.40, a PEG ratio of 2.41 and a beta of 0.42. Chemed Co. has a twelve month low of $492.84 and a twelve month high of $654.62. The stock has a fifty day simple moving average of $622.33 and a 200 day simple moving average of $589.76.

Chemed (NYSE:CHEGet Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $6.60 earnings per share for the quarter, beating analysts’ consensus estimates of $6.25 by $0.35. The business had revenue of $585.90 million during the quarter, compared to the consensus estimate of $586.64 million. Chemed had a return on equity of 32.29% and a net margin of 12.03%. Chemed’s quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the business posted $5.39 earnings per share. Research analysts expect that Chemed Co. will post 21.99 earnings per share for the current fiscal year.

Chemed Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Monday, February 26th were issued a $0.40 dividend. The ex-dividend date of this dividend was Friday, February 23rd. This represents a $1.60 dividend on an annualized basis and a yield of 0.26%. Chemed’s payout ratio is 8.93%.

Insider Activity at Chemed

In other Chemed news, VP Brian C. Judkins sold 11,158 shares of the stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $645.00, for a total transaction of $7,196,910.00. Following the completion of the sale, the vice president now directly owns 1,422 shares in the company, valued at approximately $917,190. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Chemed news, VP Brian C. Judkins sold 11,158 shares of the stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $645.00, for a total transaction of $7,196,910.00. Following the completion of the sale, the vice president now directly owns 1,422 shares in the company, valued at approximately $917,190. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Spencer S. Lee sold 2,000 shares of the stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $641.65, for a total value of $1,283,300.00. Following the sale, the executive vice president now owns 20,760 shares of the company’s stock, valued at $13,320,654. The disclosure for this sale can be found here. Insiders sold 15,808 shares of company stock worth $10,184,531 over the last three months. Company insiders own 3.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on CHE shares. Oppenheimer increased their price target on Chemed from $625.00 to $650.00 and gave the company an “outperform” rating in a research note on Thursday, February 29th. Royal Bank of Canada increased their price target on Chemed from $604.00 to $712.00 and gave the company an “outperform” rating in a research note on Monday, March 4th.

Read Our Latest Report on Chemed

About Chemed

(Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Featured Stories

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHEFree Report).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.